Moolec Science Stock Price, News & Analysis

Moolec Science (NASDAQ:MLEC) said Nasdaq Staff issued a memo recommending the Nasdaq Hearings Panel grant an exception through June 29, 2026 to regain compliance with the stockholders' equity requirement in Listing Rule 5550(b)(1), subject to disclosure conditions. The memo cites material balance-sheet improvement after Q4 2025 derecognition events.

Moolec recorded derecognition gains of approximately $91.0M, $5.2M, and $4.6M tied to loss of control of subsidiaries in December 2025 and says these items, plus intercompany liability recognition and a preference-to-ordinary conversion, substantially increased stockholders' equity.

Moolec Science S.A. (NASDAQ: MLEC) said the Nasdaq Hearings Panel granted an exception through June 29, 2026 to demonstrate compliance with the stockholders' equity requirement in Listing Rule 5550(b)(1), subject to disclosure conditions.

Moolec reported derecognition events after bankruptcy filings for certain subsidiaries that produced estimated gains of approximately $91.0 million (loss of control of Bioceres S.A.), $5.2 million (loss of control of Bioceres LLC), and $4.6 million (loss of control of Theo I SCSp). These derecognitions, intercompany eliminations and a conversion of preference shares increased the company’s stockholders' equity and, the company believes, restored Nasdaq compliance.

Moolec Science (NASDAQ:MLEC) completed a 15-for-1 share consolidation, so every 15 ordinary shares of par value US$0.10 were consolidated into 1 ordinary share with par value US$1.50.

The company said the consolidation was consummated effective as of January 5, 2026 and that the consolidation became effective on January 5, 2025 at 8:00 a.m. Eastern Time, with market quotes reflected on a consolidation-adjusted basis at the start of trading today.

Post-consolidation, issued and outstanding shares were reduced from 10,891,761 to 726,118. Shares and publicly traded warrants continue to trade under symbols MLEC and MLECW; new CUSIP numbers are G6223S125 (shares) and G6223S117 (warrants).

Moolec Science (NASDAQ:MLEC) received a Nasdaq Listing Qualifications determination letter saying it does not meet the $2.5 million minimum stockholders' equity requirement under Nasdaq Listing Rule 5550(b)(1). Management disclosed it expects to regain compliance by recognizing an estimated $105.8 million gain from derecognition of certain subsidiaries after their bankruptcy proceedings, which the company says will produce positive net income sufficient to meet Nasdaq's $500,000 net income standard. The derecognition accounting process is underway following the subsidiaries' bankruptcy filings. This announcement is made under Nasdaq Listing Rule 5810(b) to report the receipt of a non-compliance notice.

Moolec Science (NASDAQ:MLEC) announced a 15-for-1 share consolidation of its ordinary shares, effective at 8:00 a.m. ET on January 5, 2026. The consolidation will change par value from US$0.10 to US$1.50 per share and reduce issued and outstanding shares from 10,891,761 to approximately 726,118. Fractional shares will be rounded up to whole shares; no fractional share certificates will be issued. The consolidated shares will begin trading on Nasdaq Capital Market under CUSIP G6223S125 upon market open on January 5, 2026. The company says the Share Consolidation is intended to regain compliance with Nasdaq's minimum bid price rule (Rule 5550(a)(2)).

Moolec Science (NASDAQ:MLEC) announced completion of its 2025 U.S. GLASO1 safflower campaign, marking its first large-scale deployment of a plant-engineered molecular farming platform.

Key outcomes: 1,100 acres cultivated, average yield ~2,200 lb/acre versus 1,400 lb/acre in 2024 (a 57.1% YoY increase), and acreage expanded by more than 100% versus prior cycles. The company says harvests exceeded internal forecasts and validated large-volume harvest management, traceability, and quality controls.

Moolec plans to enter the U.S. nutrition and supplements market and pursue high-concentration GLA softgel applications to access premium channels and recurring demand.

Moolec Science (NASDAQ:MLEC) received a Nasdaq determination letter dated November 24, 2025, stating the company is not in compliance with Nasdaq Listing Rule 5250(c)(1) for failing to file its Annual Report on Form 20-F for year ended June 30, 2025 with the SEC.

The company attributed the delay to post-closing complexities from a mid-June 2025 business combination that triggered reverse acquisition accounting and valuation work. Moolec filed a Form 12b-25 on October 31, 2025, and requested a stay of suspension; the stay remains in effect pending a Nasdaq Hearings Panel hearing scheduled for December 18, 2025. Ordinary shares will continue trading on The Nasdaq Capital Market under the symbol MLEC during the stay. The company expects to file the Form 20-F before the hearing.

Moolec Science (NASDAQ:MLEC) received a Nasdaq determination letter dated November 14, 2025, notifying the company that its closing bid price had been below the $1.00 minimum for the last 30 consecutive business days under Nasdaq Listing Rule 5550(a)(2).

The letter indicated Nasdaq's view that the company would not receive an automatic 180-day compliance period. Moolec submitted a timely appeal to a Nasdaq Hearings Panel and requested a 180-day period to file and implement a compliance plan, which may include a reverse stock split if in shareholders' best interest.

The appeal automatically stays the determination until the hearing on December 18, 2025, and the company's ordinary shares will continue to trade as MLEC during the stay. The company said the letter does not affect its business operations or SEC reporting obligations.

Moolec Science (NASDAQ:MLEC), a biotechnology company focused on engineering plants and microbes for protein solutions, announced three significant developments. First, the company received regulatory approval from SENASA in Argentina for its safflower GLASO technology, enabling expansion of its GLA-enriched safflower crop production. Second, Moolec has doubled its U.S. safflower acreage compared to last year, strengthening its supply capabilities for the pet food and human nutrition markets.

Additionally, the company appointed Valeria Falottico as CFO, bringing over 20 years of financial expertise. Moolec also completed the integration of Mycofood™, its fungal-based protein platform, which is currently developing products for evaluation by food industry partners in North America and Europe.